Independent
Tenure on this board
4.1 yrs
Meeting calendar
ESPR · Special meeting · Wednesday, July 8, 2026
Esperion Therapeutics Inc
7 nominees · 3 ballot items.
Three proposals: (1) Approval of the Agreement and Plan of Merger (the “merger agreement proposal”); (2) Advisory (non-binding) approval of compensation to named executive officers in connection with the merger (the “advisory compensation proposal”); and (3) Approval of adjournment of the special meeting to solicit additional proxies if necessary (the “adjournment proposal”).
Market cap
$814M
1Y TSR
+191.8%
Board grade
C-
Record date
May 28, 2026
Filing
DEFM14A
Filed Jun 8, 2026 · DEFM14A
Proposals
On the ballot3
- 1
Merger Agreement Proposal
ManagementBoard: FORAdopt the Agreement and Plan of Merger dated May 1, 2026, by and among the Company, Parent and MergerCo, and approve the consummation of the merger transactions, including the merger (excluding debt financing and any Parent co-investment).
- 2
Advisory Compensation Proposal
ManagementBoard: FORNon-binding advisory vote to approve the compensation that may be paid or become payable to the Company’s named executive officers in connection with the consummation of the merger, as disclosed in the proxy statement.
- 3
Adjournment Proposal
ManagementBoard: FORApprove adjournment of the special meeting to a later date or dates, if necessary, to solicit additional proxies if there are insufficient votes to approve the merger agreement proposal at the time of the special meeting.
Director elections
Nominees on the ballot7
Independent
Tenure on this board
4.7 yrs
Also a director at
Milestone Pharmaceuticals Inc (MIST)
Independent
Tenure on this board
1.3 yrs
Also a director at
Fibrobiologics Inc (FBLG)Tuhura Biosciences Inc (HURA)
Independent
Tenure on this board
4.2 yrs
Independent
Tenure on this board
8.1 yrs
Also a director at
Inovio Pharmaceuticals Inc (INO)Ironwood Pharmaceuticals Inc (IRWD)
Independent
Tenure on this board
1.0 yrs
Independent
Tenure on this board
7.1 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | WASATCH ADVISORS LP | 6.1% | 15,768,897 | $43M |
| 2 | Two Seas Capital LP | 4.4% | 11,394,833 | $31M |
| 3 | ORBIMED ADVISORS LLCActivist | 4.1% | 10,570,300 | $29M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 10,433,760 | $29M |
| 5 | TWO SIGMA INVESTMENTS, LP | 3.7% | 9,458,779 | $26M |
| 6 | BlackRock, Inc. | 3.5% | 8,971,419 | $25M |
| 7 | BlackRock, Inc. | 2.7% | 7,071,163 | $19M |
| 8 | STATE STREET CORP | 2.7% | 7,055,794 | $19M |
| 9 | D. E. Shaw Co., Inc.Activist | 2.5% | 6,425,512 | $18M |
| 10 | MARSHALL WACE, LLP | 2.5% | 6,422,519 | $18M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Esperion Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Reference
Frequently asked questions
- When is the Esperion Therapeutics Inc 2026 special meeting?
- Esperion Therapeutics Inc (ESPR) holds its 2026 special shareholder meeting on Wednesday, July 8, 2026.
- What is the record date for the Esperion Therapeutics Inc 2026 meeting?
- The record date for the Esperion Therapeutics Inc 2026 meeting is Thursday, May 28, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Esperion Therapeutics Inc's 2026 meeting?
- The board is presenting 7 director nominees at the Esperion Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Esperion Therapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Esperion Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.